{Reference Type}: Case Reports
{Title}: A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib.
{Author}: Sakoda S;Tanaka K;Koga Y;Mikumo H;Tsuchiya-Kawano Y;Harada E;Tamiya S;Okamoto I;
{Journal}: Thorac Cancer
{Volume}: 15
{Issue}: 5
{Year}: 2024 Feb 11
{Factor}: 3.223
{DOI}: 10.1111/1759-7714.15203
{Abstract}: Metastatic inflammatory myofibroblastic tumor (IMT) is very rare and detailed reports on diagnosis and treatment are limited. Here, we report a case of metastatic IMT with ALK rearrangement. A 73-year-old woman was diagnosed with IMT involving a brain metastasis. Next generation sequencing (NGS) panel testing with Oncomine dx target test revealed that her tumor was positive for EML4-ALK. Treatment with alectinib was initiated, resulting in remarkable shrinkage of both the primary tumor and the brain metastasis. This report is the first to identify ALK rearrangement in IMT using a commercially available NGS panel testing, followed by treatment with alectinib. This case suggests that NGS panel testing may be useful in the diagnosis and treatment of patients with metastatic IMT.